Dermira (DERM) Gets a Buy Rating from Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Dermira (NASDAQ: DERM) today and set a price target of $20. The company’s shares opened today at $12.45.
“We reaffirm our Overweight rating. DERM is a leading dermatology company with pipeline advancements that could drive upward earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $20. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $20.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 11.7% and a 40.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Dermira has an analyst consensus of Moderate Buy, with a price target consensus of $15.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.42 and a one-year low of $6.98. Currently, Dermira has an average volume of 463.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne.